Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Operating Leases: 2019-2024

  • Pharming Group N.V's Operating Leases fell 9.69% to $29.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $29.9 million, marking a year-over-year decrease of 9.69%. This contributed to the annual value of $29.9 million for FY2024, which is 9.69% down from last year.
  • Pharming Group N.V's Operating Leases amounted to $29.9 million in Q4 2024, which was down 9.69% from $33.1 million recorded in Q4 2023.
  • Over the past 5 years, Pharming Group N.V's Operating Leases peaked at $33.3 million during Q4 2022, and registered a low of $10.2 million during Q4 2020.
  • Its 3-year average for Operating Leases is $32.1 million, with a median of $33.1 million in 2023.
  • In the last 5 years, Pharming Group N.V's Operating Leases spiked by 104.82% in 2021 and then fell by 9.69% in 2024.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Operating Leases stood at $10.2 million in 2020, then soared by 104.82% to $20.9 million in 2021, then skyrocketed by 59.56% to $33.3 million in 2022, then declined by 0.56% to $33.1 million in 2023, then decreased by 9.69% to $29.9 million in 2024.
  • Its last three reported values are $29.9 million in Q4 2024, $33.1 million for Q4 2023, and $33.3 million during Q4 2022.